Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Conjupro Biotherapeutics, Inc.
Filamon LTD
Atavistik Bio, Inc
PMV Pharmaceuticals, Inc
AstraZeneca
University of Michigan Rogel Cancer Center
Alterome Therapeutics, Inc.
Rutgers, The State University of New Jersey
Eli Lilly and Company
BeOne Medicines
Psyence Australia Pty Ltd
ViroMissile, Inc.
Dana-Farber Cancer Institute
Rutgers, The State University of New Jersey
Duke University
AstraZeneca
Tizona Therapeutics, Inc
University of Florida
Essen Biotech
Essen Biotech
Clasp Therapeutics, Inc.
Eli Lilly and Company
IDEAYA Biosciences
Unity Health Toronto
Daiichi Sankyo
Eli Lilly and Company
Doma Biopharmaceutical(Suzhou)Co., Ltd.
Second Life Therapeutics
Medical College of Wisconsin
Apollo Therapeutics Ltd
OHSU Knight Cancer Institute
Innate Pharma
Acerand Therapeutics Limited
MOMA Therapeutics
Mayo Clinic
Wake Forest University Health Sciences
City of Hope Medical Center
Tanabe Pharma America, Inc.
NeoTX Therapeutics Ltd.
Medtronic - MITG
DualityBio Inc.
Hospices Civils de Lyon
Georgetown University
Incyte Corporation
Maastricht University Medical Center
Vanderbilt-Ingram Cancer Center
Sahlgrenska University Hospital
National Institutes of Health Clinical Center (CC)